JP6796366B2 - 酢酸ウリプリスタルおよびその4’−アセチル類似体の合成のための工業プロセス - Google Patents
酢酸ウリプリスタルおよびその4’−アセチル類似体の合成のための工業プロセス Download PDFInfo
- Publication number
- JP6796366B2 JP6796366B2 JP2016519337A JP2016519337A JP6796366B2 JP 6796366 B2 JP6796366 B2 JP 6796366B2 JP 2016519337 A JP2016519337 A JP 2016519337A JP 2016519337 A JP2016519337 A JP 2016519337A JP 6796366 B2 JP6796366 B2 JP 6796366B2
- Authority
- JP
- Japan
- Prior art keywords
- solvent
- temperature
- group
- compound
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 28
- 238000003786 synthesis reaction Methods 0.000 title claims description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title description 5
- 238000004519 manufacturing process Methods 0.000 title description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- -1 formaldehyde acetal Chemical class 0.000 claims description 33
- 230000008569 process Effects 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 20
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 150000002466 imines Chemical class 0.000 claims description 16
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 14
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- KLKFAASOGCDTDT-UHFFFAOYSA-N ethoxymethoxyethane Chemical compound CCOCOCC KLKFAASOGCDTDT-UHFFFAOYSA-N 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 8
- NKDDWNXOKDWJAK-UHFFFAOYSA-N dimethoxymethane Chemical compound COCOC NKDDWNXOKDWJAK-UHFFFAOYSA-N 0.000 claims description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- UIOAQJNADLELPQ-UHFFFAOYSA-N C[C]1OCCO1 Chemical group C[C]1OCCO1 UIOAQJNADLELPQ-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 claims description 3
- 229910000343 potassium bisulfate Inorganic materials 0.000 claims description 3
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims description 3
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- AZFVLHQDIIJLJG-UHFFFAOYSA-N chloromethylsilane Chemical compound [SiH3]CCl AZFVLHQDIIJLJG-UHFFFAOYSA-N 0.000 claims description 2
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims 2
- 238000006640 acetylation reaction Methods 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000003747 Grignard reaction Methods 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 239000002379 progesterone receptor modulator Substances 0.000 description 3
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- PNLGKKUHDJXVFV-SRBMLKMVSA-N C[Si](OC[C@@]12[C@H](CC[C@H]1[C@@H]1CC[C@H]3CCCCC3=C1CC2)C#N)(C)C Chemical compound C[Si](OC[C@@]12[C@H](CC[C@H]1[C@@H]1CC[C@H]3CCCCC3=C1CC2)C#N)(C)C PNLGKKUHDJXVFV-SRBMLKMVSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003418 antiprogestin Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 230000003623 progesteronic effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- OHZMNOWLGDVPNW-UHFFFAOYSA-N 1-tert-butyl-4-(4-tert-butylphenyl)benzene;lithium Chemical group [Li].C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C(C)(C)C)C=C1 OHZMNOWLGDVPNW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 238000006027 Birch reduction reaction Methods 0.000 description 1
- GIEFFCXIJRRYFW-UHFFFAOYSA-N Br[BrH]Br.c1ccncc1 Chemical compound Br[BrH]Br.c1ccncc1 GIEFFCXIJRRYFW-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 0 C[C@](C[C@@]1c2ccc(*)cc2)([C@](CC2)[C@@](CC3)C1=C(CC1)C3=CC1=O)[C@]2(C(C)=O)O Chemical compound C[C@](C[C@@]1c2ccc(*)cc2)([C@](CC2)[C@@](CC3)C1=C(CC1)C3=CC1=O)[C@]2(C(C)=O)O 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ITKVLPYNJQOCPW-UHFFFAOYSA-N chloro-(chloromethyl)-dimethylsilane Chemical compound C[Si](C)(Cl)CCl ITKVLPYNJQOCPW-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- 238000005907 ketalization reaction Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003145 progesterone derivatives Chemical class 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/006—Ketals at position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Description
a)―下記の式(II)の化合物
―得られた下記の式(IV)の化合物
b)―下記の式(II)の化合物
―得られた下記の式(III)の化合物
―得られた下記の式(IV)の化合物
a)反応をより低い温度で行うことができ、且つ副反応を排除することができるため、テトラアルキルエチレンジアミンの使用は有益である;
b)17位の側鎖のケト基の形成は、反応順序の最終工程で行われるため、保護工程および脱保護工程が不要である;
c)本発明のプロセスによれば、式(I)の最終生成物は、3,3−[1,2−エタンジイル−ビス−(オキシ)]−estr−5(10),9(11)−ジエン−17−オンから出発する従来のプロセスと比較して、より少ない工程、4または5工程で得られる。
11β−[4−(N,N−ジメチルアミノ)−フェニル]−17−ヒドロキシ−19−ノルプレグナ−4,9−ジエン−3,20−ジオンの合成
融点:188〜190℃
1H NMR(500MHz,CDCl3)δ:6.95−7.01(m,2H),6.58−6.70(m,2H),5.76(s,1H),4.36(m,1H),3.12(s,1H),2.91(s,6H),2.71−2.78(m,1H),2.64(m,1H),2.59(dd,J=8.3,4.4Hz,2H),2.47−2.54(m,1H),2.29−2.46(m,4H),2.26(s,3H),1.97−2.07(m,3H),1.84−1.95(m,1H),1.69−1.80(m,1H),1.60−1.69(m,1H),1.47−1.58(m,1H),1.42(qd,J=12.0,6.1Hz,1H),0.46(s,3H)ppm
13C NMR(125MHz,CDCl3)δ:211.7,199.7,156.8,148.5,146.1,131.9,129.1,127.4,122.7,112.7,89.6,49.9,48.7,40.6,39.3,38.1,36.9,35.9,33.2,31.0,28.0,27.9,25.8,24.3,16.9ppm
11β−[4−(N,N−ジメチルアミノ)−フェニル]−17−ヒドロキシ−19−ノルプレグナ−4,9−ジエン−3,20−ジオンの合成
融点:188〜190℃
1H NMR(500MHz,CDCl3)δ:6.95−7.01(m,2H),6.58−6.70(m,2H),5.76(s,1H),4.36(m,1H),3.12(s,1H),2.91(s,6H),2.71−2.78(m,1H),2.64(m,1H),2.59(dd,J=8.3,4.4Hz,2H),2.47−2.54(m,1H),2.29−2.46(m,4H),2.26(s,3H),1.97−2.07(m,3H),1.84−1.95(m,1H),1.69−1.80(m,1H),1.60−1.69(m,1H),1.47−1.58(m,1H),1.42(qd,J=12.0,6.1Hz,1H),0.46(s,3H)ppm
13C NMR(125MHz,CDCl3)δ:211.7,199.7,156.8,148.5,146.1,131.9,129.1,127.4,122.7,112.7,89.6,49.9,48.7,40.6,39.3,38.1,36.9,35.9,33.2,31.0,28.0,27.9,25.8,24.3,16.9ppm
3,3−エチレンジオキシ−11β−[4−(2−メチル−1,3−ジオキソラン−2−イル)−フェニル]−5,17α−ビス[(トリメチルシリル)オキシ]−5α−estr−9−エン−17β−カルボニトリルの合成
融点:134〜135℃
1H NMR(800MHz,CDCl3)δ:7.34(m,2H),7.16(m,2H),4.33(m,1H),3.99−4.05(m,2H),3.96(m,1H),3.88−3.94(m,1H),3.83−3.88(m,1H),3.77−3.83(m,2H),3.73−3.77(m,1H),2.37−2.46(m,1H),2.24−2.35(m,3H),2.21(dd,J=14.4,2.6Hz,1H),2.12−2.18(m,1H),2.04(m,1H),2.08(dd J=14.4,0.9Hz,1H)1.97(ddd,J=14.8,9.1,5.5Hz,1H),1.75−1.88(m,2H),1.65−1.73(m,4H),1.64(s,3H),1.47−1.57(m,1H),1.34(m,1H),1.20(td,J=12.8,4.0Hz,1H),0.48(s,3H),0.26(s,9H),0.18(s,9H)ppm
13C NMR(200MHz,CDCl3)δ:145.9,140.3,136.2,132.6,126.9,125.1,120.9,108.8,108.4,78.8,73.5,64.5,64.5,64.4,63.4,50.1,49.0,47.2,38.9,38.6,38.6,38.5,35.6,34.9,27.4,24.6,24.5,23.5,17.0,2.6,1.1ppm
11β−(4−アセチルフェニル)−17−ヒドロキシ−19−ノルプレグナ−4,9−ジエン−3,20−ジオンの合成
1H NMR(500MHz,CDCl3)δ:7.80−7.93(m,2H),7.20−7.30(m,2H),5.79(s,1H),4.48(m,1H),3.22(br.s.,1H),2.72(dt,J=15.2,5.5Hz,1H),2.59−2.67(m,3H),2.57(s,3H),2.52(dd,J=13.3,7.9Hz,2H),2.39−2.47(m,1H),2.30−2.38(m,1H),2.20−2.30(m,4H),1.99−2.14(m,4H),1.88−1.98(m,1H),1.76−1.88(m,1H),1.66(ddd,J=15.1,9.4,6.1Hz,1H),1.55(dq,J=12.8,9.0Hz,1H),1.34−1.49(m,1H),0.40(s,3H)ppm
13C NMR(125MHz,CDCl3)δ:211.5,199.2,197.5,156.1,150.5,144.1,135.0,129.9,128.7,127.1,123.3,89.4,49.6,48.6,40.4,38.2,36.7,36.2,33.2,31.0,28.0,27.8,26.5,25.8,24.2,16.8ppm
17−アセトキシ−11β−[4−(N,N−ジメチルアミノ)−フェニル]−19−ノルプレグナ−4,9−ジエン−3,20−ジオンの合成
融点:184〜186℃
1H NMR(CDCl3,500MHz)δ:6.95−7.01(m,2H),6.61−6.69(m,2H),5.78(s,1H),4.39(d,J=7.3Hz,1H),2.91(s,6H),2.84−2.90(m,1H),2.78(ddd,J=15.0,5.6,5.3Hz,1H),2.56−2.63(m,3H),2.48−2.56(m,1H),2.42−2.48(m,1H),2.30−2.41(m,2H),2.20(d,J=13.2Hz,1H),2.13(s,3H),2.10(s,3H),2.05(dq,J=12.7,4.4Hz,1H),1.92−2.02(m,1H),1.74−1.88(m,2H),1.46−1.57(m,1H),1.32−1.42(m,1H),0.36(s,3H)ppm,
13C NMR(CDCl3,125MHz)δ:203.8,199.5,170.6,156.5,145.6,129.3,127.3,122.9,112.8,96.2,50.9,47.0,40.6,39.3,38.3,36.8,36.7,31.0,30.2,27.8,26.8,25.8,24.2,21.2,15.6ppm
17−アセトキシ−11β−(4−アセチル−フェニル)−19−ノルプレグナ−4,9−ジエン−3,20−ジオンの合成
融点:249〜252℃
1H NMR(CDCl3,500MHz):δ7.84−7.90(m,2H),7.24−7.28(m,2H),5.81(s,1H),4.50(d,J=7.6Hz,1H),2.81−2.93(m,1H),2.67−2.79(m,2H),2.63(dd,J=8.1,3.4Hz,2H),2.57(s,3H),2.41−2.55(m,2H),2.32−2.41(m,1H),2.20−2.32(m,2H),2.14(s,3H),2.08−2.12(m,1H),2.05−2.09(m,1H),1.99(td,J=12.3,6.6Hz,1H),1.76−1.91(m,2H),1.47−1.62(m,1H),1.29−1.45(m,1H),0.30(s,3H)ppm
13C NMR(CDCl3,125Mhz)δ:203.6,199.0,197.4,170.4,155.8,150.1,143.4,135.1,130.1,128.8,127.0,123.5,95.7,50.6,47.0,40.4,38.4,37.0,36.7,31.0,30.3,27.8,27.0,26.5,25.8,24.1,21.2,15.6ppm
Claims (18)
- 以下の式(I)の化合物
工程1―下記の式(II)の化合物
工程2―得られた下記の式(IV)の化合物
ことを特徴とする合成プロセス。 - 以下の式(I)の化合物
工程1―下記の式(II)の化合物
(ここでRの意味は、ジメチルアミノ基または2−メチル−1,3−ジオキソラン−2−イル基である)の5位の水酸基を、ハロゲン化溶媒、テトラヒドロフラン又はトルエン中、室温で、イミダゾールの存在下、クロロメチルシランでシリル化させ、次いで、
工程2―得られた下記の式(III)の化合物
工程3―得られた下記の式(IV)の化合物
ことを特徴とする合成プロセス。 - 前記ハロゲン化溶媒がジクロロメタンであることを特徴とする請求項1または2記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において、5〜15モル当量のメチルリチウムが使用されることを特徴とする請求項1乃至3のいずれか一項に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において、テトラアルキルエチレンジアミンとしてテトラメチルエチレンジアミンが使用されることを特徴とする請求項1乃至4のいずれか一項に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において、テトラアルキルエチレンジアミン/メチルリチウムの比率は0.5:1〜5:1であることを特徴とする請求項1乃至5のいずれか一項に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において、溶媒としてジエチルエーテル、テトラヒドロフラン、メチルテトラヒドロフラン、メチルtert−ブチルエーテル、ジイソプロピルエーテル、ジエトキシメタン、ジメトキシメタンが使用されることを特徴とする請求項1乃至6のいずれか一項に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において、溶媒としてテトラヒドロフラン、ジメトキシメタン及びジエトキシメタンが使用されることを特徴とする請求項7に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2における反応温度を−50〜(−30)℃の間に維持することを特徴とする請求項1乃至8のいずれか一項に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において得られる保護されたイミン中間体を鉱酸または有機強酸と反応させることを特徴とする請求項1乃至9のいずれか一項に記載の合成プロセス。
- 保護されたイミン中間体を塩酸、硫酸、硫酸水素カリウム、硫酸水素ナトリウム、p-トルエンスルホン酸、過塩素酸と反応させることを特徴とする請求項10に記載の合成プロセス。
- 保護されたイミン中間体を硫酸と反応させることを特徴とする請求項11に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において得られる保護されたイミン中間体の変換を水と混和できる溶媒中で実施することを特徴とする請求項1乃至12のいずれか一項に記載の合成プロセス。
- 水と混和できる溶媒が水と混和できるアルコール又はエーテルであることを特徴とする請求項13に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において得られる保護されたイミン中間体の変換をメタノール、エタノール又はテトラヒドロフラン中で実施することを特徴とする請求項12又は13に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において得られる保護されたイミン中間体の変換を0℃と使用する有機溶媒の沸点との間の温度で実施することを特徴とする請求項1乃至15のいずれか一項に記載の合成プロセス。
- 請求項1記載の工程1または請求項2記載の工程2において得られる保護されたイミン中間体の変換を20〜50℃の間の温度で実施することを特徴とする請求項1乃至15のいずれか一項に記載の合成プロセス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1300566A HU230319B1 (hu) | 2013-10-01 | 2013-10-01 | Ipari eljárás szteroid hatóanyagok előállítására |
HUP1300566 | 2013-10-01 | ||
PCT/IB2014/064979 WO2015049637A1 (en) | 2013-10-01 | 2014-10-01 | Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016533347A JP2016533347A (ja) | 2016-10-27 |
JP6796366B2 true JP6796366B2 (ja) | 2020-12-09 |
Family
ID=89991273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016519337A Active JP6796366B2 (ja) | 2013-10-01 | 2014-10-01 | 酢酸ウリプリスタルおよびその4’−アセチル類似体の合成のための工業プロセス |
Country Status (31)
Country | Link |
---|---|
US (1) | US9676814B2 (ja) |
EP (1) | EP3052513B1 (ja) |
JP (1) | JP6796366B2 (ja) |
KR (1) | KR20160062046A (ja) |
CN (1) | CN105593236B (ja) |
AR (1) | AR097878A1 (ja) |
AU (1) | AU2014330860B2 (ja) |
BR (1) | BR112016006979B1 (ja) |
CA (1) | CA2924553C (ja) |
CY (1) | CY1121286T1 (ja) |
DK (1) | DK3052513T3 (ja) |
EA (1) | EA030905B1 (ja) |
ES (1) | ES2713325T3 (ja) |
HK (1) | HK1223105A1 (ja) |
HR (1) | HRP20190414T1 (ja) |
HU (2) | HU230319B1 (ja) |
IL (1) | IL244501A0 (ja) |
LT (1) | LT3052513T (ja) |
ME (1) | ME03337B (ja) |
MX (1) | MX355222B (ja) |
MY (1) | MY176613A (ja) |
PL (1) | PL3052513T3 (ja) |
PT (1) | PT3052513T (ja) |
RS (1) | RS58252B1 (ja) |
SG (1) | SG11201601683SA (ja) |
SI (1) | SI3052513T1 (ja) |
TR (1) | TR201901381T4 (ja) |
UA (1) | UA118269C2 (ja) |
UY (1) | UY35766A (ja) |
WO (1) | WO2015049637A1 (ja) |
ZA (1) | ZA201601589B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU230381B1 (hu) * | 2014-02-17 | 2016-03-29 | Richter Gedeon Nyrt | Ipari eljárás szteroid intermedier előállítására |
CN105237607B (zh) * | 2015-10-29 | 2018-10-02 | 国家卫生计生委科学技术研究所 | 醋酸乌利司他晶k型物质及制备方法和其组合物与用途 |
CN112461957B (zh) * | 2020-11-12 | 2022-02-22 | 湖南新合新生物医药有限公司 | 一种检测醋酸乌利司他中间体ii中杂质含量的方法 |
CN112578037A (zh) * | 2020-11-12 | 2021-03-30 | 湖南新合新生物医药有限公司 | 一种检测醋酸乌利司他中间体ⅰ中乌双缩酮含量的方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
US5929262A (en) * | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
DK0900234T3 (da) * | 1996-05-01 | 2000-11-06 | Us Gov Health & Human Serv | 21-substituerede progesteronderivater anvendt som nye antigestagener |
US6020328A (en) * | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
CA2403756C (en) * | 2000-03-17 | 2010-02-09 | Hyun K. Kim | Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
AU2004217988C1 (en) * | 2003-02-28 | 2010-06-03 | Southwest Foundation For Biomedical Research | Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates |
HU227112B1 (hu) | 2006-06-14 | 2010-07-28 | Richter Gedeon Nyrt | Ipari eljárás 17-alfa-acetoxi-11-béta-[4-(N,N-dimetil-amino)-fenil]-19-norpregna-4,9-dién-3,20-dion elõállítására és új intermedierek az eljáráshoz |
HU228636B1 (en) | 2007-06-27 | 2013-04-29 | Richter Gedeon Nyrt | Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process |
CN102477060B (zh) | 2010-11-22 | 2014-08-13 | 华润紫竹药业有限公司 | 甾体化合物及其制备方法和用途 |
CN102516345B (zh) * | 2011-11-01 | 2014-11-26 | 上海优拓医药科技有限公司 | 醋酸乌利司他及其关键中间体的制备方法 |
CN103601785A (zh) * | 2013-11-25 | 2014-02-26 | 四川大学 | 一种醋酸优力斯特新的合成方法 |
-
2013
- 2013-10-01 HU HU1300566A patent/HU230319B1/hu not_active IP Right Cessation
-
2014
- 2014-10-01 PL PL14790731T patent/PL3052513T3/pl unknown
- 2014-10-01 KR KR1020167009887A patent/KR20160062046A/ko not_active Application Discontinuation
- 2014-10-01 MY MYPI2016700818A patent/MY176613A/en unknown
- 2014-10-01 AU AU2014330860A patent/AU2014330860B2/en active Active
- 2014-10-01 UY UY0001035766A patent/UY35766A/es not_active Application Discontinuation
- 2014-10-01 JP JP2016519337A patent/JP6796366B2/ja active Active
- 2014-10-01 US US15/024,822 patent/US9676814B2/en active Active
- 2014-10-01 EA EA201690467A patent/EA030905B1/ru unknown
- 2014-10-01 ES ES14790731T patent/ES2713325T3/es active Active
- 2014-10-01 SG SG11201601683SA patent/SG11201601683SA/en unknown
- 2014-10-01 EP EP14790731.5A patent/EP3052513B1/en active Active
- 2014-10-01 MX MX2016004263A patent/MX355222B/es active IP Right Grant
- 2014-10-01 SI SI201431081T patent/SI3052513T1/sl unknown
- 2014-10-01 CA CA2924553A patent/CA2924553C/en active Active
- 2014-10-01 CN CN201480054468.7A patent/CN105593236B/zh active Active
- 2014-10-01 PT PT14790731T patent/PT3052513T/pt unknown
- 2014-10-01 AR ARP140103652A patent/AR097878A1/es not_active Application Discontinuation
- 2014-10-01 RS RS20190130A patent/RS58252B1/sr unknown
- 2014-10-01 ME MEP-2019-56A patent/ME03337B/me unknown
- 2014-10-01 LT LTEP14790731.5T patent/LT3052513T/lt unknown
- 2014-10-01 WO PCT/IB2014/064979 patent/WO2015049637A1/en active Application Filing
- 2014-10-01 UA UAA201604876A patent/UA118269C2/uk unknown
- 2014-10-01 TR TR2019/01381T patent/TR201901381T4/tr unknown
- 2014-10-01 DK DK14790731.5T patent/DK3052513T3/en active
- 2014-10-01 BR BR112016006979-0A patent/BR112016006979B1/pt not_active IP Right Cessation
- 2014-10-01 HU HUE14790731A patent/HUE043002T2/hu unknown
-
2016
- 2016-03-07 ZA ZA2016/01589A patent/ZA201601589B/en unknown
- 2016-03-08 IL IL244501A patent/IL244501A0/en active IP Right Grant
- 2016-09-23 HK HK16111226.5A patent/HK1223105A1/zh unknown
-
2019
- 2019-02-27 CY CY20191100243T patent/CY1121286T1/el unknown
- 2019-03-04 HR HRP20190414TT patent/HRP20190414T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8110691B2 (en) | Industrial process for the synthesis of 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process | |
JP6796366B2 (ja) | 酢酸ウリプリスタルおよびその4’−アセチル類似体の合成のための工業プロセス | |
KR20100131018A (ko) | 에플레레논의 제조를 위한 신규 중간체 | |
EP1242444B1 (en) | Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates | |
JP3135564B2 (ja) | 11β―置換16α,17α―メチレン―エストラ―4,9―ジエン―3―オン | |
JP5250174B2 (ja) | 7α−メチルステロイドの調製方法 | |
NZ717638B2 (en) | Industrial process for the synthesis of ulipristal acetate and its 4'-acetyl analogue | |
JP2006505624A (ja) | 新規結晶型 | |
JP2004534796A (ja) | エストロゲン誘導体の製造方法 | |
Akanni et al. | Preparation of 16-formylestradiol and the 16-(α-methylenebutanolide) derivative | |
JP2004513178A (ja) | 4−(17α−メチル−置換3−オキソエストラ−4,9−ジエン−11β−イル)ベンズアルデヒド−(1Eまたは1Z)−オキシム | |
JP6453337B2 (ja) | 19−ノルプレグナ−4−エン−3,20−ジオン−17.α.−オール(ゲストノロン)の合成方法及びその中間体 | |
EP3107925B1 (en) | Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170929 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180817 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190605 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191101 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200325 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200727 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200727 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200804 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201016 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6796366 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |